

Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026

<https://marketpublishers.com/r/E0B443DBB6EEN.html>

Date: February 2016

Pages: 48

Price: US\$ 6,382.00 (Single User License)

ID: E0B443DBB6EEN

Abstracts

Benign Prostatic Hypertrophy (BPH) is a noncancerous (benign) enlargement of the prostate gland that can make urination difficult. The precise cause is not known but most likely involves changes caused by hormones, including testosterone and especially androgen dihydrotestosterone.

The prostate enlarges over time and is regarded as a normal aging process, with BPH being found to be common in males over the age of 60. However, if it is left untreated symptoms may worsen and the risks of urinary tract infections (UTIs) and acute urinary retention becomes higher and may require corrective surgery.

This report provides the current male prevalent population for BPH across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Sweden, Canada, Australia, Denmark, South Korea, Netherlands and China) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of BPH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for BPH include:

Acute urinary retention (AUR)

Recurrent UTIs

Hydronephrosis

Renal failure

Prostate cancer

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global BPH's market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of BPH and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on BPH's prevalent population.

Identify sub-populations within BPH which require treatment.

Gain an understanding of the specific markets that have the largest number of BPH patients.

Contents

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions /Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Additional data available on request

Top-Line Prevalence for Benign Prostatic Hypertrophy

Features of Clinically Diagnosed BPH Patients

Severity and Frequency of Symptoms in BPH

Urinary Incontinence and Retention in BPH

Bladder Emptying and Obstructions

Associated Co-morbid Conditions of BPH

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List Of Figures

LIST OF FIGURES

Prevalence of clinically relevant (symptomatic) BPH by age across the 17 major markets in 2016

Breakdown by country of clinically relevant BPH patients in 2016

List Of Tables

LIST OF TABLES

IPSS questionnaire for suspected BPH patients
IPSS scoring and severity
Total prevalence of BPH, males (000s)
Prevalence of clinically relevant BPH, males (000s)
IPSS severity of clinically relevant BPH patients, males (000s)
Frequency of night-time urination in clinically relevant BPH patients, males (000s)
Frequency of urinary leakage in clinically relevant BPH patients, males (000s)
Urge incontinence in clinically relevant BPH patients, (000s)
AUR with moderate / severe symptoms in clinically relevant BPH patients, (000s)
Possible bladder outlet obstruction in clinically relevant BPH patients, males (000s)
Incomplete bladder emptying in clinically relevant BPH patients, males (000s)
Erectile dysfunction in clinically relevant BPH patients, males (000s)
Prostate cancer in clinically relevant BPH patients, males (000s)
Abbreviations and acronyms used in the report
USA Prevalence of BPH disease by 5-yr age cohort, males (000s)
France Prevalence of BPH disease by 5-yr age cohort, males (000s)
Germany Prevalence of BPH disease by 5-yr age cohort, males (000s)
Italy Prevalence of BPH disease by 5-yr age cohort, males (000s)
Spain Prevalence of BPH disease by 5-yr age cohort, males (000s)
United Kingdom Prevalence of BPH disease by 5-yr age cohort, males (000s)
Brazil Prevalence of BPH disease by 5-yr age cohort, males (000s)
Japan Prevalence of BPH disease by 5-yr age cohort, males (000s)
India Prevalence of BPH disease by 5-yr age cohort, males (000s)
Turkey Prevalence of BPH disease by 5-yr age cohort, males (000s)
Sweden Prevalence of BPH disease by 5-yr age cohort, males (000s)
Canada Prevalence of BPH disease by 5-yr age cohort, males (000s)
Australia Prevalence of BPH disease by 5-yr age cohort, males (000s)
Denmark Prevalence of BPH disease by 5-yr age cohort, males (000s)
South Korea Prevalence of BPH disease by 5-yr age cohort, males (000s)
Netherlands Prevalence of BPH disease by 5-yr age cohort, males (000s)
China Prevalence of BPH disease by 5-yr age cohort, males (000s)

I would like to order

Product name: Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026

Product link: <https://marketpublishers.com/r/E0B443DBB6EEN.html>

Price: US\$ 6,382.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E0B443DBB6EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

